NEW YORK – Mission Bio said today that it has raised $70 million in a Series C funding round.
The South San Francisco-based firm said it will use the funding to scale its Tapestri singe-cell multi-omics technology, to expand the company's reach in more effective clinical trials for novel cancer treatments, as well as characterization for cell and gene therapy.
Mission Bio's Tapestri platform can simultaneously detect DNA and protein changes from the same cell, which it believes is necessary for developing impactful precision therapies.